About Heidelberg Pharma
Heidelberg Pharma is a company based in Frankfurt Am Main (Germany) founded in 1999 was acquired by Wilex in November 2010.. Heidelberg Pharma has raised $20 million across 10 funding rounds from investors including European Union, BMBF and dievini. The company has 116 employees as of November 30, 2024. Heidelberg Pharma offers products and services including ADC Technology and ATAC Technology.
- Headquarter Frankfurt Am Main, Germany
- Employees 116 as on 30 Nov, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Heidelberg Pharma Ag
-
Annual Revenue
$7.23 M (USD)-30.53as on Nov 30, 2024
-
Net Profit
$-20.47 M (USD)4.74as on Nov 30, 2024
-
EBITDA
$-25.02 M (USD)11.08as on Nov 30, 2024
-
Total Equity Funding
$20 M (USD)
in 10 rounds
-
Latest Funding Round
$540 K (USD), Grant
Apr 01, 2020
-
Investors
European Union
& 3 more
-
Employee Count
116
as on Nov 30, 2024
-
Acquired by
Wilex
(Nov 03, 2010)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Heidelberg Pharma
Heidelberg Pharma is a publicly listed company on the XETR with ticker symbol HPHA in Germany, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Heidelberg Pharma
Heidelberg Pharma offers a comprehensive portfolio of products and services, including ADC Technology and ATAC Technology. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Platform for creating antibody-drug conjugates to target cancer cells.
Utilizes Amanitin for eliminating resistant tumor cells in treatments.
Unlock access to complete
Unlock access to complete
Funding Insights of Heidelberg Pharma
Heidelberg Pharma has successfully raised a total of $20M across 10 strategic funding rounds. The most recent funding activity was a Grant round of $540 thousand completed in April 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 10
- Last Round Grant — $540,000
-
First Round
First Round
(02 Oct 2006)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2020 | Amount | Grant - Heidelberg Pharma | Valuation |
investors |
|
| Jan, 2020 | Amount | Post-IPO - Heidelberg Pharma | Valuation |
investors |
|
| Nov, 2019 | Amount | Grant - Heidelberg Pharma | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Heidelberg Pharma
Heidelberg Pharma has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include European Union, BMBF and dievini. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made in life and health sciences companies.
|
Founded Year | Domain | Location | |
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Founded Year | Domain | Location | |
|
Education and research policies are overseen by the ministry.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Heidelberg Pharma
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Heidelberg Pharma
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Heidelberg Pharma Comparisons
Competitors of Heidelberg Pharma
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Heidelberg Pharma
Frequently Asked Questions about Heidelberg Pharma
When was Heidelberg Pharma founded?
Heidelberg Pharma was founded in 1999 and raised its 1st funding round 7 years after it was founded.
Where is Heidelberg Pharma located?
Heidelberg Pharma is headquartered in Frankfurt Am Main, Germany. It is registered at Frankfurt Am Main, Hesse, Germany.
Who is the current CEO of Heidelberg Pharma?
Jan Schmidt-Brand is the current CEO of Heidelberg Pharma.
Is Heidelberg Pharma a funded company?
Heidelberg Pharma is a funded company, having raised a total of $20M across 10 funding rounds to date. The company's 1st funding round was a Grant of $14.14K, raised on Oct 02, 2006.
How many employees does Heidelberg Pharma have?
As of Nov 30, 2024, the latest employee count at Heidelberg Pharma is 116.
What is the annual revenue of Heidelberg Pharma?
Annual revenue of Heidelberg Pharma is $7.23M as on Nov 30, 2024.
What does Heidelberg Pharma do?
Heidelberg Pharma (a wholly owned subsidiary of Wilex, a Munich based public biopharma company) is a preclinical CRO and also a drug development company with a proprietary ADC technology. The companys ADC technology is based on the RNA-polymerase II inhibitor Amanitin, isolated from the Green Deathcap mushroom. Amanitin is conjugated with antibodies binding at low-copy-number antigens and the company claims that it has demonstrated outstanding activity of amanitin-based ADCs in therapy-resistant tumour cells, along with its partners. The tolerability and therapeutic window have been determined in rodent and non-human primate models. The company has also developed linkers for Amanitin based ADCs. Heidelberg Pharmas preclinical development services cater mainly to developers of anti-cancer and anti-inflammatory drugs. Their capabilities include in vivo pharmacology, DMPK, bioanalytics, molecular biology, and chemistry studies.
What products or services does Heidelberg Pharma offer?
Heidelberg Pharma offers ADC Technology and ATAC Technology.
Is Heidelberg Pharma publicly traded?
Yes, Heidelberg Pharma is publicly traded on XETR under the ticker symbol HPHA.
Who are Heidelberg Pharma's investors?
Heidelberg Pharma has 4 investors. Key investors include European Union, BMBF, dievini, and Wilex.
What is Heidelberg Pharma's ticker symbol?
The ticker symbol of Heidelberg Pharma is HPHA on XETR.